Botulinum toxin A for treating blepharospasm or hemifacial spasm

Published on 02 Sep 2019
Last Updated on 16 Sep 2025

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials, and

• Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 U and 500 U injection vials

for treating adults with blepharospasm or hemifacial spasm.

Botulinum toxin A must be administered by a neurologist trained in movement disorder or a specialist physician who has undergone training to administer botulinum toxin type A to patients with movement disorders.

Funding status

Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 2 September 2019.

Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 U and 500 U injection vials are recommended for inclusion on the MAF for the abovementioned indications from 1 November 2025.

MAF assistance does not apply to Botox 200 U injection vial or other brands of botulinum toxin A.

Botulinum toxin A for blepharospasm or hemifacial spasm (Updated 16 Sep 2025) [PDF, 150 KB]

PES Botulinum toxin A for treating blepharospasm or hemifacial spasm (Updated 16 Sep 2025) [PDF, 186 KB]